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Abstract: Nanoparticle technology is being incorporated into many areas of molecular 
science and biomedicine. Because nanoparticles are small enough to enter almost all areas 
of the body, including the circulatory system and cells, they have been and continue to be 
exploited for basic biomedical research as well as clinical diagnostic and therapeutic 
applications. For example, nanoparticles hold great promise for enabling gene therapy to 
reach its full potential by facilitating targeted delivery of DNA into tissues and cells. 
Substantial progress has been made in binding DNA to nanoparticles and controlling the 
behavior of these complexes. In this article, we review research on binding DNAs to 
nanoparticles as well as our latest study on non-viral gene delivery using 
polyethylenimine-coated magnetic nanoparticles. 
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1. Introduction 
Nanotechnology describes the creation and utilization of materials, devices, and systems through 
the control of nanometer-sized materials and their application to physics, chemistry, biology, 
engineering, materials science, medicine, and other endeavors. In particular, intensive efforts are in 
progress to develop nanomaterials for medical use as agents that can be targeted to specific organs, 
tissues, and cells. For example, magnetic nanoparticles (MNPs) are being used clinically as contrast 
agents for magnetic resonance imaging (MRI) (Table 1). MRI is a noninvasive technique that can 
provide real-time high-resolution soft tissue information [1,2]. MRI image quality can be further 
improved by utilizing contrast agents that alter proton relaxation rates [3–8]. MNP-based drug delivery 
systems (DDS) [9–11], and treatments of hyperthermia [12–21], using MNPs have been studied for 
over a decade. Furthermore, researchers have reported that MNPs have been useful in hyperthermic 
treatment for various cancers in vivo [22–31]. Nanotechnology-based anti-cancer agent DDS have 
already been approved, such as pegylated liposomal doxorubicin (DOXIL) for ovarian cancer [32–37]. 
MNPs have been used effectively as transfection reagents for introducing nucleic acids (plasmids or 
siRNAs) [38–53], or viruses (retrovirus, or adenovirus) [44,54–56] into cells. Our own research is 
focused on MNP-mediated gene delivery systems (called as “Magnetofection”). 
Table 1. Biomedical Applications of Magnetic Nanoparticles (MNPs). 
  Purpose References 
MRI  Diagnosis [1–8,57–61] 
DDS  Anti-cancer therapy, Enzyme therapy   [9–11,22–31] 
Hyperthermia  Anti-cancer therapy  [12–18,33–37] 
Gene Delivery  Anti-cancer therapy, Cell transplantation therapy  [38–55] 
2. Gene Delivery 
Gene delivery techniques efficiently introduce a gene of interest in order to express its encoded 
protein in a suitable host or host cell. Currently, there are three primary gene delivery systems that 
employ viral vectors (retroviruses and adenoviruses), nucleic acid electroporation, and nucleic acid 
transfection. These systems vary in efficacy (Table 2). Gene delivery by viral vectors can be highly 
efficient (80–90%) but may insert viral vector nucleic acid sequences into the host genome, potentially 
causing unwelcome effects, such as inappropriate expression of deleterious genes. Electroporation is 
also a highly efficient technique for introducing foreign genes into a host (50–70%); however, half of 
the recipient cells die due to the electrical stimulation. Transfection reagents do not efficiently deliver 
nucleic acids into cells (20–30%); however, cell viability is largely preserved and the method is safe 
enough for clinical use. Therefore, this method holds relatively more promise for medical applications, 
provided that its efficiency can be improved. MNPs are already in use by basic researchers to increase 
transfection efficiencies of cultured cells. Thus, MNP-nucleic acid complexes are added to cell culture 
media and then onto the cell surface by applying a magnetic force (Figure 1). Int. J. Mol. Sci. 2011, 12                 
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Table 2. Gene delivery systems. 
  Expression Type  Efficiency (%)  Cell Viability (%)  Safety 
Virus *  Stable, or Transient  80–90%  80–90%  Low 
Electroporation Transient  50–70%  40–50%  High 
TF reagent **  Transient  20–30%  80–90%  High 
* Virus including adenovirus (transient), retrovirus (stable), and lentivirus (stable); ** TF reagent, 
transfection reagents including PEI (Polysciences Inc.), FuGENE HD (Promega), and 
Lipofectamine 2000 (Invitrogen); All values are ours (unpublished experiments). 
Figure 1. MNP gene delivery system (Magnetofection). Plasmids are bound to MNPs, 
which then move from the media to the cell surface by applying a magnetic force. 
 
Oxide nanoparticles mixed with high magnetic moment compounds such as CoFe2O4, NiFe2O4, and 
MnFe2O4 exhibit superior performance compared to other magnetic materials [62,63]. However, these 
nanoparticles are highly toxic to cells, limiting their use for in vivo, and in vitro biomedical 
applications [64–67]. However, iron oxides such as magnetite (Fe3O4) and maghemite (γ-Fe2O3), in 
particular, possess high magnetic moments, are relatively safe, and currently in clinical use as MRI 
contrast agents [57–61]. These iron oxide based-magnetic materials are also suitable for biomedical 
applications. Fe
3+ is widely dispersed in the human body so leaching of this metal ion from 
nanoparticles should not reach toxic concentrations [68,69]. As a result, maghemite is a popular choice 
for MNPs used biomedical applications. It is very important to modify the surface of MNPs so that 
they can be used for biomedical applications. Thus, MNPs are coated with compounds such as natural 
polymers (proteins and carbohydrates) [70–75], synthetic organic polymers (polyethylene glycol), 
polyvinyl alcohol, poly-L-lactic acid) [72,76–78], silica [79], and gold [80,81]. These surface coating 
agents prevent nanoparticle agglomeration, cytotoxicity, and add functionality. MNPs agglomerate 
readily in aqueous solutions around pH 7 [82], and it is difficult to control the properties and amounts 
of agglomerated MNPs. The greater toxicity of MNPs compared to those of microparticles can be 
attributed to their high surface to volume ratio [83]. Coating agents prevent the leaching of potentially 
toxic components from MNPs. In fact, the cytotoxicity of uncoated NiFeO4 MNPs is dramatically Int. J. Mol. Sci. 2011, 12                 
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decreased by coating with cationic polymer, polyethylenimine (PEI) [84–86]. PEI, a cationic polymer, 
is widely used for nucleic acid transfection [87–89] and also serves as a nanoparticle dispersant [90]. 
PEI-coated MNPs enhance transfection efficiency [38,41,42,44–46,48,49,51,54,55]. 
3. Cell Transplantation Therapy Using MNPs 
Autologous cell transplantation has been widely used in the clinic for decades. Delivering therapeutic 
genes to patients using their own cells avoids using immunosuppressive drugs. We reasoned, therefore, 
that a non-viral gene delivery system using iron oxide-based MNPs could provide a powerful tool for 
next-generation therapies. Gene delivery using MNPs has been successful for delivering nucleic acids 
into living cells with high efficiency and low cytotoxicity [38,41,42,44–46,48,49,51,54,55]. Currently, 
there are several methods for inducing cellular differentiation. 
One of these methods, termed direct reprogramming, or direct conversion, has successfully yielded 
induced cardiomyocytes, induced neurons, reprogrammed pancreatic β cells, and induced pluripotent 
stem cells (iPSCs) [91–95]. Direct reprogramming represents a more straightforward strategy to treat 
diseases involving loss of function by specific cell populations compared to approaches requiring an 
intermediate embryonic stem cell. Thus, patient-derived differentiated cells by gene transfer are 
suitable for autologous cell transplantation, potentially resulting in faster patient recoveries. The 
scheme is classified into ex vivo gene therapy. The steps involved in this technique are as follows:  
(1) Patient-derived cells (such as fibroblasts) are cultured in chemically defined media in vitro;  
(2) These cells are transfected by MNPs, and differentiated into functional cells; (3) Differentiated 
cells are isolated by fluorescence-activated cell sorting (FACS); (4) FACS-purified differentiated cells 
are transplanted into the patient’s target tissue (Figure 2).  
Here we briefly describe the magnetofection [96], and our latest study concerning non-viral gene 
delivery using deacylated polyethylenimine coated MNPs. 
Figure 2. Strategy for cell transplantation therapy. A patient’s cells are cultured in 
chemically defined media. MNP-transfected cells by the introduced gene are isolated   
by FACS. FACS-purified differentiated cells are transplanted into the patient. 
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4. Gene Delivery Using MNPs and Magnetic Force 
The mechanism of magnetofection is similar to using transfection reagents (Lipofectamine 2000, 
FuGENE HD, and PEI). The only difference is that the plasmids form complexes with cationic 
polymer-coated MNPs (called as “Magnetoplex”) [42,48,97–99] (Figure 3). Figure 3 shows the two 
difference techniques. The behavior of magnetoplex is readily controlled by magnetic force. Upon 
binding to the cell surface they are taken up by endocytosis [51,100,101]. Thus, the transfection 
efficiency was increased. 
Figure 3. Gene delivery systems using a transfection reagent (cationic polymer) and 
MNPs: (A) Gene delivery system using transfection reagent. The polyplex moves randomly 
in culture medium; (B) Magnetofection system. The magnetoplex only moves to the 
cell surface. 
 
Many researchers have described magnetofection methods (Table 3). They modified the surface of 
iron oxide-based MNPs to increase transfection efficiency and reduce cytotoxicity. To achieve this, 
some investigators selected coating agents such as anionic surfactants (oleic acid, lauroyl   
sarcosinate) [42,50,102], a non-ionic water-soluble surfactant (Pluronic F-127) [42], fluorinated 
surfactant (lithium 3-[2-(perfluoroalkyl) ethylthio]propionate) [54], a polymer (polyethylene glycol,   
poly-L-lysine, poly(propyleneimine) dendrimers) [40,103,104], carbohydrates (Chitosan, Heparan 
sulfate) [41,47], silica particles (MCM48) [49], proteins (serum albumin, streptavidin) [40,55], 
hydroxyapatite [105], phospholipids [49,50], a cationic cell penetrating peptide (TAT peptide) [43],   
non-activated virus envelope (HVJ-E) [47], a transfection reagent (Lipofectamine 2000) [53], and viruses 
(adenovirus, retrovirus) [44,54–56]. These coating agents are often used in conjunction with PEI. PEI is a 
well-known cationic gene carrier with high transfection efficiency. However, the high toxicity, depended 
on its molecular weight, has limited its use as a potential gene carrier. Thus, the PEI was modified to 
increase transfection efficiency, and decrease cytotoxicity [88,106]. To enhance transfection   Int. J. Mol. Sci. 2011, 12                 
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efficiency, most researchers used the PEI, or the modified PEI to coat the nanoparticle   
surface [38,41,42,44–46,48,49,51,54,55,102,107]. PEI-coated MNPs are stable in water, bind nucleic 
acids, and control MNP behavior by magnetic force. In addition, linear PEI possesses low cytotoxicity 
compared with branched PEI in vivo and in vitro [108,109] The highest transfection efficiencies have 
been achieved using 25,000 molecular weight linear PEI [89]. However, PEI cytotoxicity due to its acyl 
groups has been described [88]. Therefore, our group focused on commercial deacylated PEI 
(Polyethylenimine “Max” (PEI “Max”), Polysciences Inc.) as an MNP (γ-Fe2O3,  d  = 70 nm, CIK 
NanoTek) coating agent. 
Deacylated polyethylenimine (linear, 25,000 molecular weight) is built from the same polymer 
backbone as the popular linear polyethylenimine, and possesses high cationic reactivity. PEI   
“Max”-coated MNPs (PEI max-MNPs) are stable in deionized water, and positively charged. Thus, 
PEI max-MNPs electrostatically bind to plasmids. We attempted to introduce the green fluorescent 
protein (GFP) gene into a mouse embryonic carcinoma cell line, P19CL6 using PEI max-MNPs, and 
succeeded in establishing a highly efficient and low cytotoxic gene delivery system [107]. 
Furthermore, we applied this system to human fetal lung-derived fibroblasts (TIG-1 cells) using six-
well plates. Using MNPs, the transfected gene’s expression level increased 2- to 4-fold under optimum 
conditions (Figure 4, unpublished data). Furthermore, to assess whether the multiple plasmids were 
expressed in a single cell, we attempt to induce the expression of three fluorescent proteins GFP, cyan 
fluorescent protein (CFP), and yellow fluorescent protein (YFP). Most cells expressed these three 
proteins (Figure 5, unpublished data) indicating that gene delivery using MNPs could introduce and 
allow expression of multiple genes in a single cell. 
Figure 4. Optimum conditions for PEI max-MNPs magnetofection. To optimize 
conditions, we varied volume (A) and time on the magnetic plate (B). These results were 
evaluated by quantitative real-time RT-PCR. The relative expression level (GFP/GAPDH) 
in the human fetal lung-derived fibroblasts (TIG-1 cells) treated with PEI max alone (A), 
and in the absence of magnetic force (0 h) (B) was defined as 1. Optimal transfection 
conditions were established when TIG-1 cells were treated with 0.8 μg PEI max-MNPs and 
2.0 μg pCAG-GFP for 8 h on the magnetic plate in either a six-well plate or a 35 mm dish. 
The asterisk (*) indicates a significant difference (P < 0.05). 
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Table 3. Summary of magnetofection literature. 
Author Year  Vector Magnetic  Nanoparticles  Modifying Agent  Targeting Cell, or Tissue  TF Efficiency  Cell Viability (% of Control) Reference 
Kami D  2011  Plasmid   Iron oxide (γ-Fe2O3)  PEI max (MW: 25 k)  P19CL6  * 82%  100%  [107] 
Pickard MR  2011  Plasmid  NeuroMag  -  Neural precursor cell  * 30%  70%  [39] 
Hashimoto M  2011 
Adenovirus, 
Biotin 
SPION  PEI, Streptoavidin  HeLa  ** 4-fold  -  [55] 
  
Adenovirus, 
Biotin 
SPION  PEI, Streptoavidin  NIH3T3  ** 10-fold  -   
  
Adenovirus, 
Biotin 
SPION  PEI, Streptoavidin  Mouse embryonic brain  -  -   
Biswas S  2011  Plasmid  Iron oxide (Fe3O4)  Aminooxy, Oxime ether  MCF-7  ** 1425-fold  89%  [110] 
B González  2011  Plasmid  SPION  Poly(propyleneimine) dendrimers  Saos-2 osteoblasts  * 12%  75%  [104] 
Zhang H  2010  Plasmid   SPION  Branch PEI (MW: 25 k)  NIT3T3  * 64%  100%  [38] 
    siRNA  SPION  Branch PEI (MW: 25 k)  NIT3T3  * 77%  100%   
Song HP  2010  Plasmid  PolyMag  Tat peptide  U251  * 60%  80%  [43] 
   Plasmid  PolyMag  Tat  peptide  Rat spinal cord  ** 2-fold  -   
Arsianti M  2010  Plasmid  Iron oxide  Branch PEI (MW: 25 k)  BHK-21  -  60–90%  [51] 
Shi Y  2010  Plasmid  Magnetite  Hyperbranch PEI (MW: 10 k)  COS-7  ** 13-fold  -  [45] 
Ang D  2010  Plasmid  Magnetite  Branch PEI (MW: 25 k)  COS-7  ** 6-fold  70%  [46] 
Tresilwised N  2010  Adenovirus  Iron oxide (Fe2O3, Fe3O4) 
Branch PEI (MW: 25 k),  
Zonyl FSA fluorosurfactant 
EPP85-181RDB **  10-fold  -  [54] 
Namgung R  2010  Plasmid  SPION  PEG, Branch PEI (MW: 25 k)  HUVEC  ** 12-fold  80%  [48] 
Yiu HH  2010  Plasmid  Iron oxide (Fe3O4) 
PEI (MW: 25 k), MCM48  
(Silica particle) 
NCI-H292 **  4-fold  -  [49] 
HC Wu  2010  Plasmid  Magnetite  Hydroxyapatite  Rat marrow stromal cells  * 60–70%  100%  [105] 
Namiki Y  2009  Plasmid  Magnetite  Oleic acid, Phospholipid  HSC45  ** 8-fold  -  [50] 
    siRNA  Magnetite  Oleic acid, Phospholipid 
Tissue sample from gastric 
cancer 
- -   
Kim TS  2009  Plasmid  PolyMag  -  Boar spermatozoa  -  -  [52] 
Kievit FM  2009  Plasmid  SPION  PEI (MW: 25 k)  C6  * 90%  10%  [41] 
    Plasmid  SPION  PEI (MW: 25 k), Chitosan  C6  * 45%  100%   
   Plasmid  PolyMag  -  C6  *  32%  66%   Int. J. Mol. Sci. 2011, 12                 
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Table 3. Cont. 
Author Year  Vector  Magnetic  Nanoparticles  Modifying Agent  Targeting Cell, or Tissue  TF Efficiency  Cell Viability (% of Control) Reference 
Lee JH  2009  siRNA  MnMEIO  Serum albumin, PEG-RGD  MDA-MB-435-GFP  * 30%  -  [40] 
Li Z  2009  Plasmid  Iron oxide  Poly-L-lysine  Lung tissue   *** 60%  -  [103] 
Yang SY  2008  Plasmid  Iron oxide (Fe3O4)  Lipofectamine 2000  He99  -  -  [53] 
    Plasmid  Iron oxide (Fe3O4)  DOTAP:DOPE  He99  -  -   
Pan X  2008  Plasmid  Magnetite 
Oleic acid, Branch PEI (MW: 25 k), 
Transferrin 
KB **  300-fold  92%  [102] 
Mykhaylyk O  2007  Plasmid  Iron oxide (Fe2O3, Fe3O4)  Branch PEI (MW: 25 k)  H441  * 49%  -  [42] 
    Plasmid  Iron oxide (Fe2O3, Fe3O4)  Pluronic F-127  H441  * 37%  -   
    Plasmid  Iron oxide (Fe2O3, Fe3O4)  Lauroyl sarcosinate  H441  -  -   
    Plasmid  Iron oxide (Fe2O3, Fe3O4) 
Branch PEI (MW: 25 k), 
 Lauroyl sarcosinate 
H441  -  -   
Morishita N  2005  Plasmid  Iron oxide (γFe2O3)  HVJ-E, protamine sulfate  BHK-21  ** 4-fold  -  [47] 
    Plasmid  Iron oxide (γ-Fe2O3)  HVJ-E, heparin sulfate  Liver, BALB/c mice (8 weeks age)  ** 3-fold  -   
Scherer F  2002  Plasmid  SPION  PEI (MW: 800 k)  NIH3T3  ** 5-fold  -  [44] 
    Adenovirus  SPION  PEI (MW: 800 k)  K562  ** 100-fold  -   
    Retrovirus  SPION  PEI (MW: 800 k)  NIH3T3  * 20%  -   
Mah C  2002  Adenovirus  Avidinylated magnetite  Biotunylated heparan sulfate  C12S  * 75%  -  [56] 
   Adenovirus  Avidinylated  magnetite  Biotunylated heparan sulfate  Adult 129/SvJ mice  -  -   
* indicates % of fluorescent positive cells analyzed by flow cytometric analysis.  
** indicates analysis by luciferase activity assay compared with control. Transfection efficiency was indicated optimal transfection condition.  
*** indicates transfection without magnetic force. 
PEI: Polyethylenimine; PEI max: Deacaylated PEI; MNP: Magnetic nanoparticle; SPION: Superparamagnetic iron oxide nanoparticle; MW: Molecular weight; TF: transfection; PolyMag: Commercial 
Magnetofection reagent), NeuroMag (Commercial Magnetofection reagent); HVJ-E: hemagglutinating virus of Japan-envelope; DOTAP: 1,2-dioleoyl- 3-trimethylammonium-propane;   
DOPE: 1,2-dioleoyl-3-sn- phosphatidyl-ethanolamine; Tat peptide: cationic cell penetrating peptide; MeMEIO: Manganese-doped magnetism-engineered iron oxide; PEG: polyethylene glycol, Zonyl FSA 
fluorosurfactant: Lithium 3-[2-(perfluoroalkyl)ethylthio]propionate). 
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Figure 5. Transfection of TIG-1 cells with multiple genes using PEI max-MNPs. TIG-1 
cells were simultaneously transfected with GFP, CFP, and YFP expression vector 
plasmids. TIG-1 cells were treated with 0.8 μg of PEI max-MNPs and 0.7 μg each of 
pCAG-GFP (GFP, provided by Dr. Nishino), pPhi-Yellow-N (YFP, Evrogen), and 
pAmCyan1-C1 (CFP, Clonetech) for 8 h on the magnetic plate in a six-well plate or a 35 
mm dish. White bar indicates 200 µm. 
 
5. Conclusions 
The great promise of gene therapy for treating devastating, incurable diseases has yet to be realized. 
Less toxic and more efficient systems will be required, and robust research efforts in this regard are 
currently underway. Rapid advances have been made in adapting nanoparticle technology for basic 
biomedical and clinical research. Nanoparticles are already being used clinically to enhance MRI 
imaging, and drug delivery for cancer patients. Our own research has focused on gene delivery 
systems for autologous cell transplantation therapy, in which the patient’s own cells are transfected 
with the gene required to correct their condition. In particular, our laboratory and those of others have 
aimed to optimize magnetofection by developing better nanoparticle coating agents [38,40–51,53–55]. 
Nanoparticle size is another important parameter but there were few reports addressing this subject [111]. 
Since cells endocytose MNPs [51,100,101], MNP size has significant implications for transfection 
efficiency. PEI-MNPs forms magnetoplex, which increased its influence on the magnetic force. 
Furthermore, MNP size influences cytotoxicity [112], and more studies on this aspect of MNP 
technology will be crucial for enhancing transfection efficiencies. 
The two research groups reported the important developments in the field of magnetofection. The 
first is the influence of the oscillating magnetic force on transfection [113,114]. The second is the use 
of MNP-heating, and -transfection [15,16]. The purpose of these studies have increased the efficiency 
of transfection, and/or induced a fever by oscillating MNPs for hyperthermia. The latter, a combination 
of MNP-heating and -transfection, was expected to research the efficacy of both hyperthermia and 
gene delivery. In the future, the studies of magnetofection using the oscillating MNPs could be 
developed as a novel methodology.  
We found that PEI is an excellent cationic polymer for dispersing MNPs and that its water 
solubility, stability, and low toxicity contribute to enhancing transfection efficiency [95,115–119]. Int. J. Mol. Sci. 2011, 12                 
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Derivation of iPSCs with the use of non-viral gene delivery using PEI max MNPs should provide a 
powerful tool for treating diseases such as Alzheimer’s, Huntington’s, and Parkinson’s by autologous 
cell transplantation. Reprogramming cells requires the action of multiple transcription factors. Our 
studies demonstrate that MNP-mediated transfection efficiently introduces at least three genes in a 
single cell. This indicates the feasibility of our system for one-step reprogramming. 
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